AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32479220 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional cash transfer intervention that paid pregnant women to deliver in a health facility
Number of subjects: 0
Study 32479220 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional cash transfer intervention
Number of subjects: 0
Study 32479220 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 616774602 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS group (n = 50)
Number of subjects: 100
Study 616774602 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 50)
Number of subjects: 100
Study 35318775 — intervention group
Group type: EXPERIMENTAL
Intervention: Execution of the planned behaviour (between-person)
Number of subjects: 90
Study 35318775 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue detection (within-person)
Number of subjects: 90
Study 35318775 — intervention group
Group type: EXPERIMENTAL
Intervention: Execution of the planned behaviour (within-person)
Number of subjects: 90
Study 32998912 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency access button (EAB) users
Number of subjects: 217510
Study 32998912 — intervention group
Group type: COMPARATOR
Intervention: Normal service (control group)
Number of subjects: 217510
Study 35648053 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive video games (IVGs) + traditional neurodevelopment treatment (TNT)
Number of subjects: 24
Study 35648053 — intervention group
Group type: COMPARATOR
Intervention: Walking training + traditional neurodevelopment treatment (TNT)
Number of subjects: 24
Study 35648053 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 34264439 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib plus paclitaxel
Number of subjects: 124
Study 34264439 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus paclitaxel
Number of subjects: 124
Study 34264439 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib plus paclitaxel in PTEN-low subgroup
Number of subjects: 124
Study 34264439 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus paclitaxel in PTEN-low subgroup
Number of subjects: 124
Study 34264439 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib plus paclitaxel in PIK3CA/AKT1/PTEN-altered subgroup
Number of subjects: 124
Study 34264439 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus paclitaxel in PIK3CA/AKT1/PTEN-altered subgroup
Number of subjects: 124
Study 32778083 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAPS intervention (nurse-led care management)
Number of subjects: 140
Study 34612724 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin tablet (4 to 24 mg/day, orally administered twice daily for 52 weeks)
Number of subjects: 109
Study 34612724 — intervention group
Group type: COMPARATOR
Intervention: Placebo (DB-placebo group)
Number of subjects: 109
Study 34612724 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin tablet (DB-blonanserin group)
Number of subjects: 109
Study 34612724 — intervention group
Group type: EXPERIMENTAL
Intervention: Blonanserin tablet
Number of subjects: 109
Study 32893428 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 420
Study 32893428 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 420
Study 32893428 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 420
Study 32893428 — intervention group
Group type: COMPARATOR
Intervention: MDI
Number of subjects: 420
Study 36052414 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram incorporating clinicopathological features and platelet-to-lymphocyte ratio (PLR)
Number of subjects: 418
Study 36052414 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram incorporating clinicopathological features and PLR
Number of subjects: 418
Study 36052414 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 418
Study 33302270 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate Seed Powder (PSP) 5 g, twice daily for 8 weeks
Number of subjects: 60
Study 33302270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 32781371 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostering Changes (FC) training programme
Number of subjects: 312
Study 32781371 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 312
Study 35253582 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based multimodal physiotherapy intervention (including pain neuroscience education, coping skills training, and therapeutic exercise) with additional supervision
Number of subjects: 33
Study 35253582 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based multimodal physiotherapy intervention (including pain neuroscience education, coping skills training, and therapeutic exercise) without additional supervision
Number of subjects: 33
Study 35253582 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 33
Study 33326562 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 43
Study 33326562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 32416538 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) HCV antibody testing by peer outreach workers
Number of subjects: 380
Study 32416538 — intervention group
Group type: COMPARATOR
Intervention: Referral to community-based HCV program for testing as usual
Number of subjects: 380
Study 33726784 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein (WP)
Number of subjects: 10
Study 33726784 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy Protein (SP)
Number of subjects: 10
Study 33726784 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study 35253686 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior reduction intervention
Number of subjects: 24
Study 33999920 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia plus spinal block
Number of subjects: 150
Study 33999920 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 150
Study 34165190 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized at-home neurofeedback (NF) training
Number of subjects: 178
Study 34165190 — intervention group
Group type: COMPARATOR
Intervention: Long-acting methylphenidate (control)
Number of subjects: 178
Study 33706336 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct breastfeeding program
Number of subjects: 60
Study 33706336 — intervention group
Group type: COMPARATOR
Intervention: Control group (education and counseling on breastfeeding)
Number of subjects: 60
Study 36156675 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus and Pomegranate Complex (CPC)
Number of subjects: 36
Study 36156675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 33710587 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 17-β-estradiol-3-phosphate eye drops (0.05% twice daily)
Number of subjects: 104
Study 33710587 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 17-β-estradiol-3-phosphate eye drops (0.1% morning, vehicle in the evening)
Number of subjects: 104
Study 33710587 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 17-β-estradiol-3-phosphate eye drops (0.1% twice daily)
Number of subjects: 104
Study 33710587 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 104
Study 33710587 — intervention group
Group type: COMPARATOR
Intervention: Topical 17-β-estradiol-3-phosphate eye drops and Vehicle
Number of subjects: 104
Study 35101086 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy combined with fluticasone propionate nasal spray
Number of subjects: 260
Study 35101086 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate nasal spray alone
Number of subjects: 260
Study 33852680 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional module (palpation prototype and registration guide instrument)
Number of subjects: 68
Study 33126335 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluconazole 800 mg/day for 2 weeks, followed by 400 mg/day for 8 weeks and 200 mg/day for 42 weeks
Number of subjects: 450
Study 33126335 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluconazole 400 mg/day for 52 weeks
Number of subjects: 450
Study 33126335 — intervention group
Group type: COMPARATOR
Intervention: No antifungal treatment
Number of subjects: 450
Study 33126335 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 450
Study 36410689 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISM intervention (manualized, brief, skills‐based intervention delivered over 6 months via two 45–60 min one‐on‐one sessions and a family meeting, supplemented by booster calls and a digital app)
Number of subjects: 0
Study 36410689 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 32895269 — intervention group
Group type: EXPERIMENTAL
Intervention: Male involvement during ANC
Number of subjects: 430
Study 35470200 — intervention group
Group type: EXPERIMENTAL
Intervention: Short video about health apps
Number of subjects: 248
Study 35470200 — intervention group
Group type: COMPARATOR
Intervention: Short video about chronic pain
Number of subjects: 248
Study 33279344 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational peer-group intervention
Number of subjects: 386
Study 33279344 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 386
Study 35603772 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth mindfulness-based cognitive therapy (MBCT-PD)
Number of subjects: 15
Study 33465546 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 300 mg
Number of subjects: 19
Study 33465546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 34579146 — intervention group
Group type: EXPERIMENTAL
Intervention: Nut consumption (30 g/d of walnuts, almonds, and hazelnuts)
Number of subjects: 0
Study 33119156 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined impact and resistance training (3 sessions per week for 6 months)
Number of subjects: 47
Study 35830145 — intervention group
Group type: EXPERIMENTAL
Intervention: DBBM and a collagen membrane
Number of subjects: 31
Study 35830145 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone from tuberosity (TUBER)
Number of subjects: 31
Study 32725216 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin plus fosfomycin
Number of subjects: 167
Study 32725216 — intervention group
Group type: COMPARATOR
Intervention: Daptomycin alone
Number of subjects: 167
Study 32554737 — intervention group
Group type: EXPERIMENTAL
Intervention: SC +BFI (standard care plus breastfeeding incentives)
Number of subjects: 168
Study 32554737 — intervention group
Group type: COMPARATOR
Intervention: SC (standard care control)
Number of subjects: 168
Study 32766762 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 1124
Study 32766762 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 1124
Study 32766762 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (overall treatment)
Number of subjects: 1124
Study 35502595 — intervention group
Group type: EXPERIMENTAL
Intervention: Olympic triathlon
Number of subjects: 15
Study 35502595 — intervention group
Group type: COMPARATOR
Intervention: Sprint triathlon
Number of subjects: 15
Study 34797440 — intervention group
Group type: EXPERIMENTAL
Intervention: Small blood loss (SBL) < 200 ml (n = 404)
Number of subjects: 1203
Study 34797440 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium blood loss (MBL) 200 ml ≤ IBL < 400 ml (n = 393)
Number of subjects: 1203
Study 34797440 — intervention group
Group type: EXPERIMENTAL
Intervention: Large blood loss (LBL) IBL ≥ 400 ml (n = 406)
Number of subjects: 1203
Study 34900846 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart watch integrated DIY-CGM
Number of subjects: 60
Study 34900846 — intervention group
Group type: COMPARATOR
Intervention: isCGM (usual care)
Number of subjects: 60
Study 35241003 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive istradefylline (20 mg/day, increasing to 40 mg/day)
Number of subjects: 100
Study 35241003 — intervention group
Group type: COMPARATOR
Intervention: Control (levodopa-containing medications only)
Number of subjects: 100
Study 32134464 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil initiation after surgery
Number of subjects: 10489
Study 32134464 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib initiation with gemcitabine
Number of subjects: 10489
Study 36200674 — intervention group
Group type: EXPERIMENTAL
Intervention: High occupational exposure
Number of subjects: 0
Study 36200674 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma and COPD coexistence
Number of subjects: 0
Study 36200674 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate exposure with asthma and COPD coexistence
Number of subjects: 0
Study 36200674 — intervention group
Group type: EXPERIMENTAL
Intervention: High occupational exposure with asthma and COPD coexistence
Number of subjects: 0
Study 34460155 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA therapy at the peak
Number of subjects: 41
Study 34460155 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA therapy at the outcome
Number of subjects: 41
Study 32232692 — intervention group
Group type: EXPERIMENTAL
Intervention: Ninjin'yoeito (NYT) 9.0 g/day
Number of subjects: 52
Study 32232692 — intervention group
Group type: COMPARATOR
Intervention: Control (no NYT)
Number of subjects: 52
Study 32232692 — intervention group
Group type: EXPERIMENTAL
Intervention: Ninjin'yoeito (NYT)
Number of subjects: 52
Study 36240945 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms-triggered approach
Number of subjects: 200
Study 36240945 — intervention group
Group type: COMPARATOR
Intervention: Fixed-scheduled approach
Number of subjects: 200
Study 33405340 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenicriviroc (AC50 of 8.9 µM)
Number of subjects: 42
Study 33405340 — intervention group
Group type: EXPERIMENTAL
Intervention: Proglumetacin (tested twice independently, with AC50 of 8.9 µM and 12.5 µM)
Number of subjects: 42
Study 33405340 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufugolix (AC50 12.6 µM)
Number of subjects: 42
Study 32407216 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2, day 1) plus cisplatin (75 mg/m2, day 1)
Number of subjects: 804
Study 32407216 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine (25 mg/m2, days 1 and 8) plus cisplatin (80 mg/m2, day 1)
Number of subjects: 804
Study 32407216 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine plus cisplatin
Number of subjects: 804
Study 32407216 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin
Number of subjects: 804
Study 36087303 — intervention group
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA 40 U
Number of subjects: 2785
Study 33983512 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg HBB intravenously
Number of subjects: 100
Study 33983512 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (2 ml)
Number of subjects: 100
Study 32957406 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological nursing intervention along with routine care
Number of subjects: 90
Study 32957406 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 90
Study 35889746 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose quadruple therapy with bismuth (two capsules of Pylera® plus 250 mg each of tetracycline and metronidazole)
Number of subjects: 46
Study 35889746 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose quadruple therapy with Lactobacillus reuteri (Gastrus®), one tablet twice-a-day for 27 days
Number of subjects: 46
Study 35889746 — intervention group
Group type: COMPARATOR
Intervention: Both groups (bismuth and Lactobacillus reuteri)
Number of subjects: 46
Study 32253042 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% HCSP
Number of subjects: 48
Study 32253042 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% HCSP
Number of subjects: 48
Study 32253042 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HCSP
Number of subjects: 48
Study 32253042 — intervention group
Group type: COMPARATOR
Intervention: 0% HCSP
Number of subjects: 48
Study 32253042 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HCSP increase
Number of subjects: 48
Study 36971803 — intervention group
Group type: EXPERIMENTAL
Intervention: Process-responsible nursing (PP)
Number of subjects: 400
Study 36971803 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 400
Study 33159999 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraminidase inhibitors (NAIs) for influenza B treatment; specific dosage and duration not mentioned.
Number of subjects: 0
Study 33159999 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerase inhibitor baloxavir in high-risk influenza B patients; specific dosage and duration not mentioned.
Number of subjects: 0
Study 33159999 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 32164439 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer screening (LCS) by low-dose computed tomography (LDCT)
Number of subjects: 986
Study 32164439 — intervention group
Group type: COMPARATOR
Intervention: Known COPD
Number of subjects: 986
Study 32164439 — intervention group
Group type: COMPARATOR
Intervention: Undiagnosed COPD
Number of subjects: 986
Study 32164439 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry findings added to LDCT
Number of subjects: 986
Study 32164439 — intervention group
Group type: EXPERIMENTAL
Intervention: Airflow obstruction (GOLD 1 and 2)
Number of subjects: 986
Study 32164439 — intervention group
Group type: EXPERIMENTAL
Intervention: Airflow obstruction (GOLD 3 and 4)
Number of subjects: 986
Study 32164439 — intervention group
Group type: EXPERIMENTAL
Intervention: Emphysema (mild)
Number of subjects: 986
Study 32164439 — intervention group
Group type: EXPERIMENTAL
Intervention: Emphysema (moderate)
Number of subjects: 986
Study 32164439 — intervention group
Group type: EXPERIMENTAL
Intervention: Emphysema (severe)
Number of subjects: 986
Study 35799647 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified wristband
Number of subjects: 260
Study 35799647 — intervention group
Group type: COMPARATOR
Intervention: Traditional wristband
Number of subjects: 260
Study 34446666 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased resident agitation
Number of subjects: 379
Study 34446666 — intervention group
Group type: EXPERIMENTAL
Intervention: For-profit ownership
Number of subjects: 379
Study 34288117 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0
Study 33932482 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time functional near infrared spectroscopy-based neurofeedback training
Number of subjects: 0
Study 33932482 — intervention group
Group type: COMPARATOR
Intervention: Sham neurofeedback
Number of subjects: 0
Study 32679568 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) at 60%-90% HR reserve
Number of subjects: 30
Study 32679568 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Aerobic Continuous Training at 50%-65% HR reserve
Number of subjects: 30
Study 32679568 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal daily physical activity)
Number of subjects: 30
Study 33409756 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard IVF insemination
Number of subjects: 577
Study 33409756 — intervention group
Group type: COMPARATOR
Intervention: ICSI insemination
Number of subjects: 577
Study 34162777 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical consultation targeting outpatients by a pharmacist
Number of subjects: 33
Study 34162777 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention (no pharmaceutical consultation)
Number of subjects: 33
Study 35384630 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory workplace intervention with individual guidance by an occupational physiotherapist (OPT)
Number of subjects: 107
Study 35384630 — intervention group
Group type: COMPARATOR
Intervention: Standard counselling and guidance by an OPT without workplace intervention
Number of subjects: 107
Study 33941677 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (anodal and cathodal)
Number of subjects: 0
Study 33941677 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study 32601011 — intervention group
Group type: EXPERIMENTAL
Intervention: Yakson
Number of subjects: 90
Study 32601011 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle Human Touch (GHT)
Number of subjects: 90
Study 32601011 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 34784108 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (0.5 g single oral PZA)
Number of subjects: 24
Study 34784108 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (0.5 g single oral PZA)
Number of subjects: 24
Study 33164264 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Daoyin (PD) programme, 2 times a day, 5 days/week for 2 months
Number of subjects: 96
Study 33164264 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (stationary cycle ergometer), 30 min/day, 5 days/week for 2 months
Number of subjects: 96
Study 33164264 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintaining usual activities)
Number of subjects: 96
Study 33164264 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Daoyin (PD) programme
Number of subjects: 96
Study 33164264 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Daoyin (PD) programme and Exercise group
Number of subjects: 96
Study 34290666 — intervention group
Group type: EXPERIMENTAL
Intervention: High-concentration oxygen treatment [FiO280 (8 L/min)] for 6 hours
Number of subjects: 600
Study 34290666 — intervention group
Group type: COMPARATOR
Intervention: Low-oxygen treatment [FiO230 (2 L/min)] for 6 hours
Number of subjects: 600
Study 32398304 — intervention group
Group type: EXPERIMENTAL
Intervention: CFTR Phe508del carriers
Number of subjects: 108034
Study 32398304 — intervention group
Group type: COMPARATOR
Intervention: Non-carriers
Number of subjects: 108034